Four Doses of MAGE Vaccine for Patients With Squamous Cell Carcinoma of the Head and Neck

  • STATUS
    Recruiting
  • participants needed
    48
  • sponsor
    University of Maryland
Updated on 7 November 2020
cancer
carcinoma
squamous cell carcinoma

Summary

Squamous Cell Carcinoma of the Head and Neck (SCCHN) effects 43,000 individuals in the United States annually with an estimated overall survival of 50%. For some patients who develop local or distant metastases following primary therapy, surgery is not an option. This study is being done to test the safety of experimental cancer vaccines made of MAGE-A3 and HPV-16 antigens. We also hope to learn what doses of the vaccine will best stimulate the immune system. There will be 2 cohorts in this study, based on the results of tumor testing: Cohort 1: Patients with tumor that is HPV 16 positive Cohort 2: Patients with tumor that is MAGE-A3 positive The doses of vaccine in both cohorts will be 500, 1000, or 1500 micrograms depending on when the patient is enrolled in the trial. Each vaccine treatment is every 2 weeks for 8 weeks, for a total of 4 vaccines doses.

Description

Tests performed during this phase will assess the potential patients eligibility to participate in this study. The following will occur at this visit: 1. Review and completion of Health Insurance Portability and Accountability Act (HIPAA) consent and protocol informed consent documents Assessment of inclusion/ exclusion criteria Demographics and descriptive factors Physical examination Medical history Vital signs (blood pressure [BP], pulse rate, body temperature, body weight and heart rate.) Hematology Chemistry Thyroid-stimulating hormone (TSH) CT/PET Tumor biopsy to determine MAGE-A3 AND HPV 16 expression. Blood draw for HLA typing Concomitant medication recording Quality of Life (QOL) and Eastern Cooperative Toxicity Group (ECOG) status Serum pregnancy test Physical tumor measurements. Immune response blood draw (ELISPOT, recall assays, restimulation assays, tetramers, sequencing of MAGE-A3 and HPV 16- specific DNA, antigenic profiling) Review contraceptive plan. Prior to study enrollment, patients are to be seen by the Medical Oncologist and Surgical Oncologist. A consensus will be reached that the patient is or is not a suitable candidate for this trial based upon the Inclusion and Exclusion criteria. If after the Screening of a potential study subject for eligibility the subject does not meet eligibility requirements, he or she will not be enrolled into the study, after consensus is made by the aforementioned physicians. The blood and tissue specimens obtained by the screened but ineligible subject will be stored for subsequent analysis. If during the Screening Process the patient is unable to continue with Screening due to an illness, a family matter or other personal matter beyond that individuals control, and falls out of the Screening timeframe of 30 days as stated in the protocol, that patient can be re-screened at a later date if the individual wishes. In this case, the patient will be re-consented and re-screened. TREATMENT PHASE Day 1, Treatment #1 The following will occur at this visit: Assessment of Inclusion/ Exclusion Criteria (these will be reassessed prior to the first vaccination to ensure patient eligibility) Physical examination Hematology and chemistry (obtained 24 hours prior to visit) Concomitant medication recording Adverse event recording QOL and ECOG status Serum pregnancy test (obtained 24 hours prior to visit) Physical tumor measurements. Immune response blood draw (ELISPOT, recall assays, restimulation assays, tetramers, sequencing of MAGE-A3 and HPV 16- specific DNA, antigenic profiling) Review contraceptive plan Review patient diary Administer vaccine treatment #1 Vital signs (BP, pulse rate, body temperature, body weight and heart rate.) evaluated pre dose and 0.5, 1, 2 and 4 hrs post-dose Evaluate injection site, evaluated immediately post-injection, 0.5, 1, 2 and 4 hrs post-dose Day 15, Treatment #2 (+/-3 days) The following will occur at this visit: Physical examination Adverse event recording QOL and ECOG status Physical tumor measurements. Immune response blood draw (ELISPOT, recall assays, restimulation assays, tetramers, sequencing of MAGE-A3 and HPV 16- specific DNA, antigenic profiling) Review contraceptive plan Review patient diary Administer vaccine treatment #2 Vital signs (BP, pulse rate, body temperature, body weight and heart rate.) evaluated pre dose and 0.5, 1, 2 and 4 hrs post-dose Evaluate injection site, evaluated immediately post-injection, 0.5, 1, 2 and 4 hrs post-dose Day 29, Treatment #3 (+/-3 days) The following will occur at this visit: Physical examination Chemistry (obtained 24 hours prior to visit) Concomitant medication recording Adverse event recording QOL and ECOG status Physical tumor measurements. Immune response blood draw (ELISPOT, recall assays, restimulation assays, tetramers, sequencing of MAGE-A3 and HPV 16- specific DNA, antigenic profiling) Review contraceptive plan Review patient diary Administer vaccine treatment #3 Vital signs (BP, pulse rate, body temperature, body weight and heart rate.) evaluated pre dose and 0.5, 1, 2 and 4 hrs post-dose Concomitant medication recording Evaluate injection site, evaluated immediately post-injection, 0.5, 1, 2 and 4 hrs post-dose Day 43, Treatment #4 (+/-3 days) The following will occur at this visit: Physical examination Adverse event recording QOL and ECOG status Physical tumor measurements. Immune response blood draw (ELISPOT, recall assays, restimulation assays, tetramers, sequencing of MAGE-A3 and HPV 16- specific DNA, antigenic profiling) Review contraceptive plan Review patient diary Administer vaccine treatment #4 Vital signs (BP, pulse rate, body temperature, body weight and heart rate.) evaluated pre dose and 0.5, 1, 2 and 4 hrs post-dose Concomitant medication recording Evaluate injection site, evaluated immediately post-injection, 0.5, 1, 2 and 4 hrs post-dose POST-TREATMENT PHASE Post-Treatment Phase, Follow Up, Day 57 (+/- 3days) The following will occur at this visit: Physical examination Vital signs Tumor biopsy (unless in the view of the PI no tumor site is safely amenable for biopsy) Concomitant medication recording Adverse event recording QOL and ECOG status Physical tumor measurements. Immune response blood draw (ELISPOT, recall assays, restimulation assays, tetramers, sequencing of MAGE-A3 and HPV 16- specific DNA, antigenic profiling) Review contraceptive plan Review patient diary Post- Treatment Phase, Month 3 through Month 24/ End of Study Follow Up (+/-7 days) The following will occur at these visits: Physical examination Vital signs Hematology Chemistry Concomitant medication recording Adverse event recording QOL and ECOG status Physical tumor measurements. Immune response blood draw (ELISPOT, recall assays, restimulation assays, tetramers, sequencing of MAGE-A3 and HPV 16- specific DNA, antigenic profiling) Review contraceptive plan Review patient diary

Details
Condition Squamous cell carcinoma, head and neck cancer
Treatment MAGE-A3 HPV-16 vaccine
Clinical Study IdentifierNCT00704041
SponsorUniversity of Maryland
Last Modified on7 November 2020

Eligibility

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note